Skip to main content
. 2022 Oct 3;2022(10):CD013337. doi: 10.1002/14651858.CD013337.pub2

Mondal 2014.

Methods Randomised, placebo‐controlled
Participants Schizophrenia
N = 123
Interventions

  1. Olanzapine alone (olanzapine group)

  2. Olanzapine plus metformin 1000 mg/d (metformin group)

  3. Olanzapine plus topiramate 100 mg/d (topiramate group)


41 participants in each group
Outcomes Planned assessments included body weight, waist circumference, fasting glucose, insulin and insulin resistance, blood pressure and lipid profile, SAPS, SANS
Notes Only an abstract is available but with no extractable data. We emailed study authors for more details but we did not receive a response.

SANS: Scale for the Assessment of Negative Symptoms; SAPS: Scale for the Assessment of Positive Symptoms